Phase 2 N=21 Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age
Chronic Oral Food Refusal
Primary: % Calories Taken Orally — 68.62; 76.89 change in percent kcal obtained orally
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=70 iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children
Feeding Behavior · Feeding Disorder of Infancy or Early Childhood
Primary: Participants Who Transitioned to Oral Feeding — 23; 24 Participants
N/A N=116 Study of Refeeding to Optimize iNpatient Gains
Anorexia Nervosa
Primary: Number of Participants With Clinical Remission at Different Time Points of Assessment — 12; 8; 10; 13 Participants — p=0.42
Phase 2 N=16 D-cycloserine and Treatment of Feeding Disorders
Feeding Disorders · Specific Phobia
Primary: Rapid Swallowing — 18.6; 14.3 percentage of bites
N/A N=30 Parent Acceptance and Commitment Therapy (PACT) for Parents of Children With Pediatric Feeding Disorder
Pediatric Feeding Disorder, Chronic · Pediatric Feeding Dysfunction, Acute
Primary: Patient Health Questionnaire-9 (PHQ-9) — 2; 0; 12; 0 Participants
Phase 3 N=129 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
Eosinophilic Gastrointestinal Disorders (EGIDs) · Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants in Histologic Remission (<15 Eos/Hpf) — 34.3; 40.3 percentage of participants — p=0.58
N/A N=20 Chewing and Oral Processing of Solid Food
Dysphagia
Primary: Number of Chewing Cycles Per Bolus — 22; 15; 15; 28 number of chewing cycles
N/A N=600 Evaluating Oral Nutritional Supplements on Children's Nutritional Status and Digestive Health in Vietnam.
Undernutrition · Wasting · Malnourished
Primary: Improvement of Digestive Disorders and Anorexia Nervosa — 219; 212; 175; 155 participants
Phase 3 N=63 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids
Eosinophilic Esophagitis · Eosinophilic Gastrointestinal Disorders (EGIDs)
Primary: Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks — -14.3; -21.6 units on a scale — p=0.04
Phase 2 N=18 Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Prader Willi Syndrome
Primary: Occurence of Adverse Event — 10; 9; 6 number of adverse events
Early Phase 1 N=25 Milk Oral Immunotherapy in Children to Treat Food Allergy
Milk Hypersensitivity
Primary: Number of Subjects Who Completed Desensitization Protocol — 6; 12 participants
Phase 1 N=15 Peanut Oral Immunotherapy in Children With Peanut Allergy (Peanut Flour)
Peanut Allergic Subjects
Primary: Determine the Percentage of Patients Tolerating the 12-month DBPCFC — 2; 10 Participants
N/A N=177 Shifting Perspectives: Enhancing Outcomes in Anorexia Nervosa With CRT
Anorexia Nervosa
Primary: Change in Cognitive Flexibility - Condition 4 Trail Making Test of DKEFS — 11.89; 10.94; 11.47; 11.14 score on a scale — p=.507
N/A N=159 Development of Eating Disorders Symptoms Among Children
Eating Disorders Symptoms
Primary: Number of Participants With >20 on the 26 Children Eating Attitudes Test — 26; 4 Participants
Phase 2 N=146 Peanut Oral Immunotherapy in Children
Peanut Hypersensitivity
Primary: Percentage of Participants Desensitized to Peanut Protein After 134 Weeks of Oral Immunotherapy (OIT) — 71; 2 Percentage of Participants — p=<0.0001
N/A N=30 Effect of Managing Problematic Eating Behaviours With Dietary Management on Chronic Disease Self-management
Hypertension · Type 2 Diabetes
Primary: The Change in EEQ (Emotional Eater Questionnaire) Score is the Primary Outcome Measure in This Study. — -1.7; -3.2 Scores on a scale
N/A N=71 Learning to Love Mealtime Together
Infant Obesity · Parenting · Feeding Behavior
Primary: Infant Weight-for-Length Z Scores — 0.43; 0.12 z-score — p=0.07
N/A N=10 Novel Blood Test to Predict Safe Foods for Infants and Toddlers With Food Protein-induced Enterocolitis Syndrome (FPIES)
Food Protein-Induced Enterocolitis Syndrome · Allergies · Pediatric Disorder
Primary: Negative Predictive Value (NPV), Defined as the Percentage of Test-predicted Safe Foods That Are Actually Safe Foods. — 98.5; 73.16 percentage — p=<0.0001
N/A N=237 Habituation to Food as a Risk Factor for Pediatric Obesity
Obesity in Children
Primary: Change in zBMI — -0.048; 0.013; 0.011 z-score — p=0.051
N/A N=34 Healthy Start to Feeding Intervention
Weight, Body · Diet Habit
Primary: Weight-for-Length Percentile — 44.94; 46.70; 58.69; 48.54 Percentile
N/A N=32 The RELISH Study: Compliance and Palatability of Oral Nutritional Supplements in Hospitalised Older Adults
Malnutrition
Primary: Percentage of the Mean Oral Nutritional Supplement Consumed Per Day (%) — 26.31; 66.8 percentage of supplement consumed — p=0.01
Phase 2 N=32 Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome
Prader-Willi Syndrome · Hyperphagia
Primary: Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) — -6.08; -6.64 score on a scale
N/A N=78 Behavioral & Nutritional Treatment to Help CF Preschoolers Grow
Cystic Fibrosis · Pancreatic Cystic Fibrosis
Primary: Change in Energy Intake From Baseline to Post Treatment — 485; 58 kilocalories per day — p=<0.001
N/A N=22 Cold Milk for Dysphagia in Preterm Infants
Dysphagia of Newborn
Primary: Percentage of Infants With Improvement of Dysphagia — 58 Percentage of patients
Phase 2 N=38 Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Hyperphagia in Prader-Willi Syndrome
Primary: Change From Baseline in Hyperphagia in Prader-Willi Syndrome (PWS) Questionnaires- Responsiveness (HPWSQ-R) Total Score at End-of-treatment (Day 15) — -15.6; -8.9 score…
Phase 2 N=15 Intranasal Oxytocin for Infants With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Suck and Swallow Competency in Infants/Children With PWS Who Are in Nutritional Phase 1a — 8; 4; 1; 1 Participants — p=0.930
N/A N=105 FoodRx for Obesity Treatment
Obesity · Food Insecurity
Primary: Percent Change in Total Body Weight at 24 Weeks (BWL+VOUCHER and BWL+HOME vs BWL-Alone) — -2.7; -3.0 Percent initial weight loss
Phase 4 N=147 Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis
Diarrhea
Primary: Number of Participants That Were Successfully Rehydrated — 57; 49 Participants — p=0.28
N/A N=23 The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
Food Allergy
Primary: Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy — 6; 4; 3 participants
Phase 2 N=20 Time-limited Specific Oral Tolerance Induction in Children With Severe Egg Allergy
- Egg Hypersensitivity
Primary: Number of Children That Achieved Total (40 ml) or Partial (Less Than 40 ml But at Least 10 ml) Tolerance to Raw Egg — 9; 0 participants